Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Receivables (2018 - 2025)

Fate Therapeutics (FATE) has disclosed Change in Receivables for 7 consecutive years, with $233000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 139.63% year-over-year to $233000.0, compared with a TTM value of -$2.6 million through Dec 2025, down 335.76%, and an annual FY2025 reading of -$2.6 million, down 335.76% over the prior year.
  • Change in Receivables was $233000.0 for Q4 2025 at Fate Therapeutics, up from -$713000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $28.3 million in Q4 2022 and bottomed at -$25.0 million in Q1 2023.
  • Average Change in Receivables over 5 years is -$260050.0, with a median of -$650500.0 recorded in 2024.
  • The sharpest move saw Change in Receivables skyrocketed 1970.11% in 2022, then plummeted 1373.2% in 2023.
  • Year by year, Change in Receivables stood at $1.4 million in 2021, then surged by 1970.11% to $28.3 million in 2022, then tumbled by 98.98% to $288000.0 in 2023, then crashed by 304.17% to -$588000.0 in 2024, then surged by 139.63% to $233000.0 in 2025.
  • Business Quant data shows Change in Receivables for FATE at $233000.0 in Q4 2025, -$713000.0 in Q3 2025, and -$1.0 million in Q2 2025.